The tumor suppressor p53 is mutationally inactivated in Ϸ50% of human cancers. Approximately one-third of the mutations lower the melting temperature of the protein, leading to its rapid denaturation. Small molecules that bind to those mutants and stabilize them could be effective anticancer drugs. The mutation Y220C, which occurs in Ϸ75,000 new cancer cases per annum, creates a surface cavity that destabilizes the protein by 4 kcal/mol, at a site that is not functional. We have designed a series of binding molecules from an in silico analysis of the crystal structure using virtual screening and rational drug design. One of them, a carbazole derivative (PhiKan083), binds to the cavity with a dissociation constant of Ϸ150 M. It raises the melting temperature of the mutant and slows down its rate of denaturation. We have solved the crystal structure of the proteinPhiKan083 complex at 1.5-Å resolution. The structure implicates key interactions between the protein and ligand and conformational changes that occur on binding, which will provide a basis for lead optimization. The Y220C mutant is an excellent ''druggable'' target for developing and testing novel anticancer drugs based on protein stabilization. We point out some general principles in relationships between binding constants, raising of melting temperatures, and increase of protein half-lives by stabilizing ligands.
T
he tumor suppressor p53 is a key protein in the cell's defense against cancer. If p53 and its associated cell-cycle pathways are active, then p53 will arrest the cell cycle of a potentially cancerous cell and induce apoptosis (1, 2) . It is such a potent tumor suppressor that it or its pathways must be inactivated by mutation for cancer to proceed. p53 is inactivated directly by mutation in Ϸ50% of human cancers. It has a complex structure, being composed of several domains (reviewed in ref. 3) . Nearly all of the oncogenic mutations occur in its core or DNA-binding domain, contained within the sequence of residues 94-292 (4, 5) . The core domain of wild-type protein is rather unstable, with a melting temperature of Ϸ44°C and a short half-life of Ϸ9 min at body temperature (6) (7) (8) . Many of the oncogenic mutants are inactivated simply because their stability is lowered so that the protein denatures very rapidly and is either too unstable to function at body temperature or rapidly depleted by denaturation and aggregation (9) .
In principle, destabilized mutants of p53 can be stabilized by the binding of other molecules, as shown by the binding of a specific double-stranded DNA (6), heparin (10) , or a designed peptide (11) . Those molecules are targeted against wild-type p53 core domain and should bind generically to most mutants. Other molecules have been proposed to stabilize the folded state of the core domain of p53 [e.g., CP-31398 (12) ], but, unlike the aforementioned examples, do not bind reversibly to the core domain (10, 13, 14) and promote anticancer effects in vivo via routes other than thermal stabilization of p53 (15) .
We have proposed an alternative strategy to stabilizing p53 in a generic mode: the targeting of specific lesions in the protein that are induced by mutation so a drug may be designed that binds tightly to a mutation-induced binding site but weakly to wild-type p53 (5, 16) . Y220C is the ninth most frequent p53 cancer mutant and accounts for an estimated 75,000 new cancer cases per annum worldwide based on cancer incidence statistics by the World Health Organization and reported mutation frequencies (www-p53.iarc.fr) (17) . The mutation creates a surface crevice, and the protein is highly destabilized as a result (16) . Importantly, this crevice is distant from the surface regions that are known to be involved in DNA recognition or proteinprotein interactions, making it a particularly attractive target site for stabilizing small-molecule drugs. Here, we have: discovered a family of molecules that bind to the cavity of the oncogenic mutant Y220C using in silico screening based on the crystal structure and NMR screening within selected compounds; measured the binding of a representative compound, PhiKan083, to the target cavity using NMR spectroscopy; confirmed the dissociation constant by various biophysical methods; and shown that it raises the apparent melting temperature of the Y220C mutant and slows down the rate of thermal denaturation. We have solved the crystal structure of PhiKan083 bound to the mutant Y220C, thus identifying the residues of the protein that are in contact with the small molecule, which will provide a template for the design of drugs that may be therapeutically important. els [supporting information (SI) Fig. S1 ] in MOE (22), (ii) ligand docking into the crystal structure with GOLD (23, 24) and rescoring of the best poses to form a consensus score (Fig. S2) , and (iii) manual selection from the consensus hit lists according to criteria of medicinal chemistry and crystallography (Fig. 1 ). (Fig. 3B ).
Primary in Vitro Screening
The kinetics of denaturation of T-p53C-Y220C at 310 K (37°C) was fitted to a simple binding model for PhiKan083 (Fig.  3C ). In the absence of ligand, the protein had a half-life of 3.8 min. This increased to 15.7 min at saturating concentrations of PhiKan083.
Crystal Structure of PhiKan083 Bound to T-p53C-Y220C and Implications for Drug Design. We solved the crystal structure of the T-p53C-Y220C:PhiKan083 complex at 1.5-Å resolution by soaking the small molecule into crystals of the mutant (Fig. 5A , Table  1 ). One of the two molecules in the asymmetric unit (chain B) showed unambiguous electron density for a PhiKan083 molecule bound to the mutation-induced surface cleft (Fig. 5C ), whereas the pocket was partly occupied in chain A (Fig. S4) . The central carbazole moiety is largely buried in the cleft, with the 9-ethyl group occupying the deepest part of the hydrophobic pocket (Fig. 5B) . Binding would appear to have an important contribution from hydrophobic packing interactions. The ethyl group is in close contact to the sulfhydryl group of the mutated residue Cys-220, which adopts two alternative conformations, and a number of hydrophobic side chains (Phe-109, Leu-145, Val-147, and Leu-257), thus anchoring the ligand to the pocket. The planar carbazole ring system is sandwiched between the hydrophobic side chains of Pro-222 and Pro-223 on one side, and Val-147 and Pro-151 on the other side of the binding cleft. The ring nitrogen sits close to the position of the hydroxyl group of the tyrosine residue in the wild-type structure (1.0-Å distance) (Fig. 5E ). The N-methylmethanamine moiety forms a hydrogen bond with the main-chain carbonyl of Asp-228 (2.7-Å distance). Only very small structural shifts occur upon ligand binding to the mutant. The residues that are within 5 Å of PhiKan083 (residues 109, 145-147, 150, 151, 220-223, 228-230, and 257) superimpose with a rmsd of 0.3 Å (all atoms). The most significant shift is observed for the side chain of Thr-150, which is displaced by up to 1.4 Å upon binding, thus widening the entrance of the pocket (Fig. 5D ).
The occupancy of PhiKan083 in the binding pocket upon soaking is significantly different in the two molecules in the asymmetric unit, even though the architecture of the crystal lattice would suggest a similar accessibility of both sites. In subunit A, however, parts of the S7/S8 loop (residues 225 and 226) interact with a neighboring molecule, whereas this region is not engaged in packing interactions in molecule B. In this packing arrangement, the structural plasticity required for efficient binding may be reduced in chain A. Moreover, in the ligand-free structure of the mutant (PDB ID code 2J1X), the side chain of Thr-230 inside the binding pocket adopts two alternative conformations in molecule A (but not in molecule B), which may hamper effective binding to molecule A upon soaking of the crystals, because one of these conformations narrows the bottom of the binding pocket ( Fig. 5F ).
Comparison of modeled and observed binding modes nicely shows how relatively small changes in the protein environment that occur upon ligand binding can be crucial for the accuracy of binding-mode predictions. If the ligand is docked to chain A of the free structure with the C␥-methyl group of the Thr-230 side chain occupying part of the binding site (purple structure in Fig.  5F ), the anchoring ethyl group is positioned at Ϸ1.5 Å from its actual binding position (rmsd of the whole ligand, 6.0 Å), and the carbazole is flipped by 180°, placing the amine group at the opposite end of the binding pocket. Furthermore, this altered binding mode corresponds to a dramatic decrease in predicted affinity, as represented by its DrugScore CSD value (26) ( Table 2 ). In contrast, if the ligand is docked into the structure of the complex (after removing the coordinates of the bound ligand), i.e., taking the observed small induced-fit movements of the protein residues into account, the modeled binding mode (yellow molecule in Fig. 5F ) almost perfectly matches the observed binding mode (green molecule in Fig. 5F ). Small induced-fit structural changes bedevil in silico screening methods, and so it is important to have solved the structure of the complex. Even small changes in the structures of substrates and ligands have been known from early studies to cause radical changes in modes of binding (27) .
Inspection reveals contacts, where the central, hydrophobic carbazole scaffold contacts a polar atom. The hydroxyl of Thr-150 at the entrance of the cleft, for example, is in close contact to C5 of the bound carbazole (3.5 Å). Probably more crucially, the main-chain oxygen of Leu-145 at the bottom of the cleft is only 3.3 Å away from C1 of the carbazole ring system. In the unligated structure (PDB ID code 2J1X), this carbonyl group forms a hydrogen bond with a water molecule that is displaced upon ligand binding (Fig. 5D ). These observations indicate that a substantial increase in binding energy, and hence a lower dissociation constant, should be achieved through structureguided modification of the central scaffold, e.g., by providing a hydrogen-bond donor for the carbonyl of Leu-145 or by replacing part of the aromatic structure by suitable nonaromatic bioisosteres (28) (29) (30) . Moreover, the part of the crevice that preexists in the wild type is not addressed by the binding mode of PhiKan083, which offers the potential for substantial extension of the ligand to create additional stabilizing interactions. Further hit optimi- zation could, therefore, combine ligand-based SAR data with structure-based design (31, 32) .
Conclusions
We have demonstrated that the site of mutation in the oncogenic Y220C mutant is a druggable target. PhiKan083 binds to it with reasonable affinity. The crystal structure of the complex will be a starting point for further rounds of drug design and refinement. Because the site of mutation does not appear to be in a region of the protein that is functionally important, it is an excellent target for drug stabilization therapy. The degree of stabilization given by a drug is related to: Fig. S5 . Further, the half life of the mutant protein is significantly increased by the drug, and the increase will be greater for future generations of drugs that have more intrinsic binding energy. There is every possibility that an anticancer drug could be developed for the Y220C mutant using compounds that bind more tightly than the current lead.
Methods

Materials. T-p53C-Y220C
for protein crystallography was purified as described (16, 33) . For biophysical measurements and NMR spectroscopy, we used a pET24a-HLTV-derived vector (courtesy of M. D. Allen, Medical Research Council Centre), containing an N-terminal fusion of a 6xHis/lipoamyl domain/TEV protease cleavage site sequence. Expression and purification followed published protocols (34) . The N-terminally fused 6xHis/lipoamyl domain sequence was removed by TEV protease digestion. PhiKan059 and PhiKan083 were obtained from Enamine, Ltd.
Biophysical Methods. Isothermal titration calorimetry. Binding was measured with an isothermal titration calorimeter (VP-ITC, MicroCal) (35) at 20°C in a 25 mM sodium phosphate buffer (pH 7.2), 150 mM NaCl, and 1 mM DTT. For binding of PhiKan083 to T-p53C-Y220C, 5 mM PhiKan083 in 5% d6-DMSO in buffer was titrated into the sample cell containing 100 M protein in 5% d6-DMSO in buffer. The DMSO content was matched using a high-precision Mettler Toledo balance. Injection steps were 10 l (first injection, 3 l) with 600-s spacing. Further data evaluation was done by using the MicroCal Origin program. NMR spectroscopy. The low-molecular-weight compounds were dissolved in d6-DMSO to make 10 mM stock solutions. To screen compound mixtures by chemical-shift mapping, 10 l each of four different compounds were mixed together, and 25 l of this mixture was added to 25 l of D2O and 500 l of 70 M T-p53C-Y220C (in 25 mM sodium phosphate, 150 mM NaCl, and 5 mM DTT, pH 7.2). The final concentration for each compound was 114 M at a concentration of 4.5% (vol/vol) d6-DMSO. NMR samples were freshly prepared and kept sealed under argon after degassing. 1 H/ 15 N HSQC correlation spectra were acquired at 20°C on Bruker AvanceIIϩ 700 and Avance 800 spectrometers using a 1 H/ 13 C/ 15 N triple resonance inverse, cryogenic 5-mm probe (Bruker), with the following parameters: 16 scans, 128 complex points in t1, recycle time of 0.95 sec, and 1,024 total points in t2. Using Bruker's TopSpin 2.0 software, the number of complex points in t1 was doubled by forward-complex linear prediction, and shifted squared sine bell window functions were applied to both dimensions before zero filling and Fourier transformation. A digital resolution of 2.0 Hz per point in the 1 H frequency dimension and 4.7 Hz per point in the 15 N frequency dimension was used. Spectra were analyzed by using Sparky 3.113 (36) . Thermal stability. Thermal unfolding was followed either by differential scanning calorimetry as described in ref. 37 at a scan rate of 250 K/h or by monitoring unfolding by the binding of the dye SYPRO Orange (5ϫ) using a Rotor-gene 6000 (Corbett Life Science) at 270 K/h in 25 mM sodium phosphate, 150 mM NaCl, and 5 mM DTT, pH 7.2, with a protein concentration of 10 M. Time-dependent fluorescence studies. Unfolding kinetics was performed as described by Friedler et al. (11) at 37°C in 50 mM Hepes, pH 7.2, 1 mM Tris-2-carboxyethylphosphine, by following the emission of tryptophan at 340 nm on excitation at 280 nm (6), using a Cary Eclipse fluorescence spectrophotometer controlled by the supplied Cary software. Reactions were followed for 10,000 s. Data were fitted to a single exponential followed by a linear-drift term.
X-Ray Crystallography Methods. Crystals of T-p53C-Y220C in space group
P212121 with two molecules in the asymmetric unit were grown at 21°C by sitting-drop vapor diffusion under the conditions described in ref. 16 . PhiKan083 was soaked into crystals of T-p53C-Y220C by stepwise addition of cryo buffer (19% polyethylene glycol 4,000, 20% glycerol, 10 mM sodium phosphate, pH 7.2, 100 mM Hepes, pH 7.2, 150 mM KCl) with increasing concentration of PhiKan083 over a period of 2 h. After reaching the final concentration of 10 mM, soaking was continued for another 30 min before the crystals were flash frozen in liquid nitrogen. An x-ray dataset to 1.5-Å resolution was collected at 100 K on beamline I04 at the Diamond Light Source. Data processing was performed by using Mosflm (38) and Scala (39) . Structure solution and refinement were performed with CNS (40) . After an initial round of rigid body refinement using the structure of free T-p53C-Y220C (PDB ID code 2J1X) as starting model, the structure of the complex was refined by iterative cycles of refinement with CNS and manual model building with MAIN (41) . Water molecules were added to the structure by using the water-pick option implemented within CNS and manual model building. At this stage of the refinement, PhiKan083 was built into the model of chain B, and the structure was further refined, including incorporation of alternative conformations for selected side chains. For the cavity in chain A, we observed . Plotted is the increase in Tm for a protein where ⌬S ϭ 400 cal/mol/K, the approximate value for the core domain of p53.
